4th Annual Gene Therapy for Neurological Disorders (description)


Address:425 Summer St Boston, Massachusetts, United States of America 02210
Event dates:12/5/2022 - 12/8/2022 (This event has already taken place)
Event web site:
findCE GPA: This event is not yet rated. Click here to view a sample report card
Click here to rate 4th Annual Gene Therapy for Neurological Disorders


Topics to be Covered:

  • Anna Kajaste-Rudnitski, Group Leader, San Raffaele Hospital
  • David Huss, Chief Scientific Officer, Shape Therapeutics
  • Jacinthe Gingras, Senior Director - Ophthalmology and Neurology, Homology Medicines
  • Kennon Smith, Lead Scientist - Platform, Stridebio
  • Science, Health and Medicine
  • Pharmaceuticals
Organizer phone:+16174554188
Offering type:Conference
Specialty:Data not provided
Event frequency:Never
First Meeting:
Total events:
Est. attendance:
Target audience:Any
Other target audiences:
Host Sponsor:Hanson Wade
Est. # of exhibitors:
Currency:US Dollars
Language:Data not provided
CE Credits:
Organizer URL


This December, the 4th Annual Gene Therapy for Neurological Disorders meeting is returning to Boston to welcome discovery, preclinical, translational and clinical industry scientists to share, learn and network for the shared goal of successfully and safely delivering gene therapies to the CNS.

Join the expanding audience of gene therapy experts seeking to overcome the translational hurdles of developing gene therapies for CNS targets, from discovery, preclinical, translational, clinical, and commercial departments at the likes of Capsigen, AviadoBio, AskBio,Novartis, Prevail Therapeutics,Passage Bio,Voyager Therapeutics,UniQure and more.

Group discounts and early booking rates are available. Please visit the website for full pricing information.


Speakers: Allie Stanton, Phd Candidate - Pardis Sabeti Lab, Harvard Medical School, Maria Praggastis, Staff Scientist Regeneron, Pharmaceuticals, Sharyl Fyffe-Maricich, Executive Director - Molecular and Cellular Biology Research, Ultragenyx, Shyam Ramachandran, Neuroscience Head - Genomic Medicine Unit, Sanofi, Anindya Sen, Director - Pre-Clinical Research and Development, Prevail Therapeutics, Edgar Rodriguez, Chief Executive Officer and Co-Founder, Lacerta Therapeutics, Samir Koirala, Director, Biogen, Zhenpeng Qin, Associate Professor of Mechanical Engineering, University of Texas at Dallas, Boaz Levi, Associate Investigator - Human Cell Types, Allen Institute, Martin Ingelsson, Professor and Clinician Scientist, Tanz Centre for Research In Neurodegenerative Diseases, University of Toronto, Rodolphe Clerval, Chief Executive Officer, Coave Therapeutics, Steven Cohen, Executive Director, Daiichi Sankyo, Elizabeth Ramsburg, Head Of Central Nervous System and Research, Spark Therapeutics, Jay Barth, Chief Medical Officer, Lexeo Therapeutics, Lingzhi Zhao, Senior Director - Gene Therapy and Transnational Discovery, AGTC, Ruby Boyanapalli, Associate Director, Takeda, Benjamin Shykind, Senior Director - Discovery, Prevail Therapeutics, Eric Schaeffer, Chief Scientific Officer, Paros Bio, Heather Lau, Executive Director, Ultragenyx Pharmaceutical, Roger Chung, Chief Scientific Officer, Celosia Therapeutics, Amber Van Laar, Vice President, Clinical Development, AskBio, Brittany Hernandez, Executive Vice President, Crossroad Strategies, Bryn Martin, Vice President, Research, Precision Delivery, and CSF Sciences, Alcyone Therapeutics, Inc, Jennifer Johnston, Cofounder and Chief Executive Officer, NysnoBio, Kristin Stephenson, Director - Strategy and Alliances, St. Jude Children's Research Hospital, Laura Jane Smith, Principle Scientist and Scientific Co-founder, Homology Medicines, Mark Tuszynski, Professor, University of California, School of Medicine, Ken Mullinix, Head of Surgical Services, Biomere, Peter Pechan, Head of Vector Biology, GTVC, UCB Boston, Serene Forte, Senior Vice President, Head of Genetic Medicine, Relief Therapeutics, Amy Brin, Executive Director and CEO, The Child Neurology Foundation, Ben Deverman, Director of Vector Engineering, Stanley Center for Psychiatric Research, Broad Institute, Thomas Packard, Associate Director, Shape Therapeutics


08:00 to 14:30

Registration Fee Details:

Industry Rate - FULL ACCESS PASS: Conference + Workshop Day AND Post Conference Vector Day: USD 4893.00,
Industry Rate - Conference + Workshop Day Or Post Conference Vector Day: USD 3996.00,
Industry Rate - Conference Only: USD 3099.00,
Academic Rate - FULL ACCESS PASS: Conference + Workshop Day AND Post Conference Vector Day: USD 3893.00,
Academic Rate - Conference + Workshop Day Or Post Conference Vector Day: USD 3296.00,
Academic Rate - Conference Only: USD 2699.00

Other items that tuition includes:

Travel and hotel arrangements:

Contact Person:Emily Lincoln
Organizer State/Province: (Outside US)
Organizer CountryData not provided
Organizer Phone+16174554188
Structural makeupData not provided
Host Sponsor; Other SponsorsHanson Wade
Event Site/VenueThe Westin Seaport District
Event sold out?No
Multiple locations or dates?No
Statistics available for most recent event held in:NA
Average number in event attendance of:
Number in attendance of:
Target BoundariesInternational
Is Registration contact information the same as Organizer Contact above?Yes
Web Page
Can one register for your CE on your web site?NA
Can registration be made by snail (regular) mail?Yes
Online housing reservations: 
Do you have additional written or AV materials for sale?No
If so, are they available for non-attendees as well as those attending?NA
Is full tuition necessary to ensure registration?No
Will there be shuttle service available?NA
Additional notes:


Sign In/Sign Out
About Us
Contact Us